Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

2.

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.

Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B, Packman K, Rosen N, Boylan JF, Heimbrook D, Niu H.

Cancer Res. 2011 Aug 15;71(16):5535-45. doi: 10.1158/0008-5472.CAN-10-4351. Epub 2011 Jun 24.

3.

Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models.

Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, Moliterni J, Huby N, Fotouhi N, Liu M, Goelzer P, Sandhu HK, Li JK, Railkar A, Heimbrook D, Niu H.

Mol Cancer Ther. 2010 Jan;9(1):134-44. doi: 10.1158/1535-7163.MCT-09-0601. Epub 2010 Jan 6.

4.

Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.

Daouti S, Wang H, Li WH, Higgins B, Kolinsky K, Packman K, Specian A Jr, Kong N, Huby N, Wen Y, Xiang Q, Podlaski FJ, He Y, Fotouhi N, Heimbrook D, Niu H.

Cancer Res. 2009 Mar 1;69(5):1924-32. doi: 10.1158/0008-5472.CAN-08-2627. Epub 2009 Feb 24.

5.

A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.

Daouti S, Li WH, Qian H, Huang KS, Holmgren J, Levin W, Reik L, McGady DL, Gillespie P, Perrotta A, Bian H, Reidhaar-Olson JF, Bliss SA, Olivier AR, Sergi JA, Fry D, Danho W, Ritland S, Fotouhi N, Heimbrook D, Niu H.

Cancer Res. 2008 Feb 15;68(4):1162-9. doi: 10.1158/0008-5472.CAN-07-2349.

6.

Development of comprehensive functional genomic screens to identify novel mediators of osteoarthritis.

Daouti S, Latario B, Nagulapalli S, Buxton F, Uziel-Fusi S, Chirn GW, Bodian D, Song C, Labow M, Lotz M, Quintavalla J, Kumar C.

Osteoarthritis Cartilage. 2005 Jun;13(6):508-18.

7.

Chondrocyte cluster formation in agarose cultures as a functional assay to identify genes expressed in osteoarthritis.

Quintavalla J, Kumar C, Daouti S, Slosberg E, Uziel-Fusi S.

J Cell Physiol. 2005 Aug;204(2):560-6.

PMID:
15799031
8.

A structure-activity analysis of the cloned rat and human Y4 receptors for pancreatic polypeptide.

Walker MW, Smith KE, Bard J, Vaysse PJ, Gerald C, Daouti S, Weinshank RL, Branchek TA.

Peptides. 1997;18(4):609-12.

PMID:
9210181

Supplemental Content

Loading ...
Support Center